Carregant...
The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy and Metabolic Effects
BACKGROUND: A current limitation of islet transplantation is reduced long term graft function. The glucagon like peptide-1 (GLP-1) receptor agonist, exenatide (Byetta(®), Amylin Pharmaceuticals, CA) has properties that could improve existing islet function, prevent further loss of islet mass and pos...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2772201/ https://ncbi.nlm.nih.gov/pubmed/18622276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0b013e31817c4ab3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|